NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OVID

Ovid Therapeutics Inc

Jul 03 • 04:00PM ET

0.3384

Dollar change +0.0079
Percentage change 2.39	%

Healthcare • Biotechnology • USA • NASD

Peers: PTCT FOLD RARE SRPT CRSP EDIT NTLA BLUE QURE SGMO

| Held by: VTI VXF IWM VTWO IWO BSVO VTWG IWC MSSM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	16.32%	Shs Outstand	71.11M	Perf Week	-1.34%
Market Cap	24.06M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	-0.02%	Shs Float	59.51M	Perf Month	13.29%
Enterprise Value	-4.51M	PEG	-	EPS next Q	-0.16	Inst Own	54.79%	Short Float	4.20%	Perf Quarter	-0.47%
Income	-24.97M	P/S	43.75	EPS this Y	-67.46%	Inst Trans	-4.67%	Short Ratio	2.95	Perf Half Y	-64.64%
Sales	0.55M	P/B	0.41	EPS next Y	-5.57%	ROA	-23.42%	Short Interest	2.50M	Perf YTD	-63.76%
Book/sh	0.83	P/C	0.56	EPS next 5Y	-	ROE	-36.31%	52W High	1.47 -76.98%	Perf Year	-60.75%
Cash/sh	0.60	P/FCF	-	EPS past 3/5Y	- 24.72%	ROIC	-34.52%	52W Low	0.24 39.55%	Perf 3Y	-82.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-86.05% -	Gross Margin	-10.22%	Volatility	8.25% 8.95%	Perf 5Y	-95.61%
Dividend TTM	-	EV/Sales	-8.20	EPS Y/Y TTM	51.00%	Oper. Margin	-10404.20%	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.93	Sales Y/Y TTM	15.73%	Profit Margin	-4557.12%	RSI (14)	56.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.93	EPS Q/Q	12.88%	SMA20	8.50%	Beta	0.17	Target Price	2.88
Payout	-	Debt/Eq	0.24	Sales Q/Q	-12.16%	SMA50	10.10%	Rel Volume	0.33	Prev Close	0.33
Employees	23	LT Debt/Eq	0.22	Earnings	May 13 BMO	SMA200	-51.89%	Avg Volume	848.31K	Price	0.34
IPO	May 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.82% 162.10%	Trades		Volume	276,889	Change	2.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy	$9
Apr-29-24	Initiated	H.C. Wainwright	Buy	$9
Apr-05-24	Initiated	Wedbush	Outperform	$8
Dec-21-23	Initiated	BTIG Research	Buy	$11
Oct-13-23	Initiated	Oppenheimer	Outperform	$8
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral	$4
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$5
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral	$10 → $4
Sep-04-19	Initiated	RBC Capital Mkts	Outperform	$12
Apr-20-18	Initiated	Ladenburg Thalmann	Buy	$27

Show Previous Ratings

Jun-25-25 08:00AM	Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties (GlobeNewswire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart)
Jun-05-25 07:30AM	Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 (GlobeNewswire)
May-13-25 09:15AM	Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.30%
08:00AM	Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
07:50AM	Loading…
May-12-25 07:50AM	Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-09-25 08:10AM	ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates (Zacks)
May-06-25 05:20PM	Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates (Zacks) -5.87%
10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-01-25 07:40AM	Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 08:15AM	Incyte (INCY) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-02-25 08:00AM	Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +9.78%
Mar-11-25 09:10AM	Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors (GlobeNewswire) -6.92%
08:00AM	Loading…
Feb-27-25 08:00AM	Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-05-25 08:00AM	Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.04%
Jan-30-25 09:55AM	Ovid Therapeutics upgraded at Oppenheimer as OV329s promise quite real (TipRanks) -5.57%
Dec-02-24 08:00AM	Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-12-24 09:30AM	Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -8.82%
08:00AM	Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 08:00AM	Ovid Therapeutics to Host Investor Event (GlobeNewswire)
Sep-26-24 08:00AM	Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin (GlobeNewswire)
Sep-20-24 04:00AM	After epilepsy setback, Ovid charges confidently ahead in CNS (Pharma Voice)
Sep-11-24 08:00AM	Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth (GlobeNewswire)
Sep-04-24 08:00AM	Ovid Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-20-24 12:00PM	Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why (Zacks)
Aug-13-24 09:10AM	Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
08:00AM	Loading…
Aug-08-24 08:00AM	Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer (GlobeNewswire)
Jul-30-24 08:00AM	Ovid Therapeutics to Present at Upcoming August Investor Conferences (GlobeNewswire)
Jul-23-24 08:00AM	Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists (GlobeNewswire)
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace)
Jul-15-24 10:45AM	Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Jul-10-24 08:00AM	eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures (GlobeNewswire) +5.31%
Jul-01-24 08:00AM	Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations (GlobeNewswire) +12.09%
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-17-24 01:45PM	Is the Stock Market Closed on Juneteenth 2024? (InvestorPlace) -76.00%
01:28PM	ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation (InvestorPlace)
01:03PM	AAN Stock Alert: The Aaron's Company Pops 33% on Take-Private Deal (InvestorPlace)
12:38PM	Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? (InvestorPlace)
08:07AM	Takeda drug for rare types of epilepsy misses goal in late-stage trial (BioPharma Dive)
06:55AM	Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat (GlobeNewswire)
May-28-24 01:09PM	3 Sorry Penny Stocks to Sell in May While You Still Can (InvestorPlace)
May-20-24 06:00AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
May-14-24 01:54PM	OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +6.95%
09:10AM	Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 07:00AM	Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
Apr-30-24 07:23AM	B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target (MT Newswires) -8.68%
Apr-29-24 07:18AM	HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target (MT Newswires) +7.74%
Apr-26-24 10:00AM	Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-04-24 08:00AM	Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-24 05:19PM	5 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-08-24 08:00AM	Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 08:00AM	Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -5.51%
Feb-06-24 08:00AM	Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-01-23 07:30AM	Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) (GlobeNewswire) +7.39%
Nov-09-23 12:00PM	Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why (Zacks) -5.65%
08:48AM	Q3 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-05-23 07:15PM	Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-03-23 08:00AM	Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Oct-19-23 10:44AM	These 2 Strong Buy Penny Stocks Have Massive Upside Potential, Says Oppenheimer (TipRanks)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire) -7.13%
Oct-10-23 08:00AM	Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire)
Sep-29-23 03:16PM	20 Countries With Highest Rate of Epilepsy (Insider Monkey)
Sep-26-23 07:30AM	Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023 (GlobeNewswire)
Sep-20-23 07:30AM	Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-30-23 08:00AM	Ovid Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.07%
Aug-15-23 09:38PM	3 Very Promising Penny Stocks That Are Flying Under the Radar (InvestorPlace) +5.29%
Aug-04-23 09:15AM	Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +5.42%
08:00AM	Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Aug-01-23 08:00AM	Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-31-23 09:29PM	Madison Avenue Partners, LP Boosts Stake in Ovid Therapeutics Inc (GuruFocus.com)
Jul-02-23 10:00AM	Ovid Therapeutics Inc.'s (NASDAQ:OVID) hedge funds investors lost 12% last week but have benefitted from longer-term gains (Simply Wall St.)
Jun-28-23 08:00AM	Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer (GlobeNewswire)
Jun-26-23 08:00AM	Ovid Therapeutics Added to Russell 3000® Index (GlobeNewswire) -8.58%
May-22-23 06:43AM	Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth (Simply Wall St.)
May-05-23 08:45AM	Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-01-23 06:00AM	Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors (GlobeNewswire)
Apr-27-23 02:30PM	Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.73%
Apr-12-23 12:00PM	Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know (Zacks) +6.57%
Apr-11-23 06:51AM	Ovid Therapeutics (NASDAQ:OVID) shareholders have endured a 73% loss from investing in the stock five years ago (Simply Wall St.) +7.45%
Apr-10-23 08:00AM	Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-15-23 06:21AM	Ovid Therapeutics Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-13-23 08:00AM	Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 08:00AM	Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum (GlobeNewswire) -10.42%
Mar-08-23 08:00AM	Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures (GlobeNewswire)
Feb-28-23 08:00AM	Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-08-23 08:00AM	Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments (GlobeNewswire) -5.14%
Jan-22-23 07:37AM	Ovid Therapeutics Inc. (NASDAQ:OVID) has caught the attention of institutional investors who hold a sizeable 29% stake (Simply Wall St.)
Jan-05-23 08:00AM	Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial (GlobeNewswire)
Dec-02-22 10:00AM	Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022) (GlobeNewswire)
Nov-17-22 07:23AM	Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 08:00AM	Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-18-22 08:57AM	Ovid Therapeutics (NASDAQ:OVID) shareholders have endured a 77% loss from investing in the stock five years ago (Simply Wall St.)
Sep-27-22 08:00AM	Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALEXANDER MARGARET A.	President and COO	Feb 26 '25	Sale	0.56	5,279	2,956	73,406	Feb 28 04:15 PM
Rona Jeffrey A	CBFO	Feb 26 '25	Sale	0.56	3,902	2,185	67,973	Feb 28 04:15 PM
ALEXANDER MARGARET A.	President and COO	Jan 27 '25	Buy	0.73	6,810	4,971	34,935	Jan 29 09:18 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OVID

Ovid Therapeutics Inc

Upgrade your FINVIZ experience